公开(公告)号：US10857144B2

公开(公告)日：2020-12-08

申请号：US16408931

申请日：2019-05-10

Applicant: Bow River LLC

Inventor： Sundar Srinivasan ,  Christina Chow

IPC: A61K31/4468 ,  A61K31/4995 ,  A61K31/454 ,  A61K31/519 ,  A61K31/4745 ,  A61K31/397 ,  A61K31/498 ,  A61K31/497 ,  A61K31/5395 ,  A61K31/506 ,  A61K31/407 ,  A61P35/04 ,  A61P35/02 ,  A61K9/00 ,  A61K9/08 ,  A61K31/5383 ,  A61P25/18 ,  A61P25/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K9/10

Abstract: The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US10556860B2

公开(公告)日：2020-02-11

申请号：US15779132

申请日：2016-11-30

Applicant: Arizona Board of Regents on Behalf of the University of Arizona

Inventor： Laurence Hurley ,  Vijay Gokhale ,  HyunJin Kang ,  Kui Wu

IPC: A61K31/5377 ,  A61K31/505 ,  A61K31/4995 ,  A61K31/4402 ,  A61K31/17 ,  C07C275/54 ,  C07D401/12 ,  C07D403/04 ,  C07D239/34 ,  C07D239/52 ,  C07D241/18 ,  C07D295/088 ,  A61P35/00 ,  C07D219/08

Abstract: The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the characterization of the effect of hTERT core promoter region mutants on the 5-12 G-quadruplex structure and its stability. It is believed that some of the compounds of the invention bind selectively to the G-quadruplex in the hTERT core promoter mutant, which results in reversal of the effect of mutant promoter activation.

公开(公告)号：US20200038471A1

公开(公告)日：2020-02-06

申请号：US16661036

申请日：2019-10-23

Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

Inventor： Matthew R. Pincus ,  Josef Michl ,  Ehsan Sarafraz-Yazdi

IPC: A61K38/03 ,  A61K45/06 ,  C07K14/47 ,  A61K38/17 ,  A61K38/10 ,  A61K31/4995 ,  A61K31/155 ,  A61K47/54

Abstract: A method of treating cancer in a subject, including: providing a subject having a plurality of cancer cells; and administering to the subject, a therapeutically effective amount of a composition including: an HDM-2 binding component; and a membrane resident component, the membrane resident component bound to the HDM-2 binding component. Also provided are a method of selectively necrosing cancer cells, a method of causing membranolysis in cancer cells, and a cancer treatment composition.

公开(公告)号：US20200030327A1

公开(公告)日：2020-01-30

申请号：US16525203

申请日：2019-07-29

Applicant: Gilead Sciences, Inc.

Inventor： Elbert Chin ,  Darryl Kato ,  John O. Link ,  Nathan Shapiro ,  Zheng-Yu Yang

IPC: A61K31/506 ,  C07D487/08 ,  A61K31/4995 ,  A61P31/18

Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

公开(公告)号：US20200016136A1

公开(公告)日：2020-01-16

申请号：US16465622

申请日：2018-01-02

Applicant: VIIV HEALTHCARE UK (NO. 5) LIMITED

Inventor： Michael S. BOWSHER ,  Jeffrey DESKUS ,  Kyle J. EASTMAN ,  Eric P. GILLIS ,  David B. FRENNESSON ,  Christiana IWUAGWU ,  B. Narasimhulu NAIDU ,  Kyle E. PARCELLA ,  Kevin M. PEESE ,  Mark G. SAULNIER ,  Prasanna SIVAPRAKASAM

IPC: A61K31/444 ,  C07D401/14 ,  C07D413/14 ,  C07D491/048 ,  C07D491/08 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/519 ,  A61K31/497 ,  A61K31/5386 ,  A61K31/4995 ,  C07D471/08 ,  C07D417/14 ,  A61K31/541 ,  C07D491/147 ,  A61P31/18

Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

公开(公告)号：US10456396B2

公开(公告)日：2019-10-29

申请号：US15422382

申请日：2017-02-01

Applicant: Oyster Point Pharma, Inc.

Inventor： Douglas Michael Ackermann, Jr. ,  James Loudin ,  Kenneth J. Mandell

IPC: A61K31/4995 ,  A61K9/00 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/4427 ,  A61K31/4985 ,  A61K45/06 ,  A61K9/08

Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.

公开(公告)号：US20190248747A1

公开(公告)日：2019-08-15

申请号：US16201117

申请日：2018-11-27

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： Ravi K. Amaravadi ,  Jeffrey Winkler

IPC: C07D215/46 ,  A61K31/4375 ,  C07D401/12 ,  A61K31/4709 ,  A61K31/4706 ,  A61K31/4995 ,  A61K31/436 ,  A61K31/7056 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/704

CPC classification number: C07D215/46 ,  A61K31/436 ,  A61K31/4375 ,  A61K31/4545 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/704 ,  A61K31/7056 ,  C07D401/12 ,  Y02A50/411 ,  A61K2300/00

Abstract: The invention provides novel asymmetric and symmetric bisaminoquinolmes and related compounds, methods of treatment and syntheses. The novel compounds exhibit effective anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.

公开(公告)号：US10344031B2

公开(公告)日：2019-07-09

申请号：US16101753

申请日：2018-08-13

Applicant: Dr. Reddy's Laboratories Ltd.

Inventor： Pradip Kumar Sasmal ,  Shahadat Ahmed ,  Ashok Tehim ,  Vidyadhar Paradkar ,  Prasanna M. Dattatreya ,  Nanjegowda Jagadeesh Mavinahalli

IPC: A61K31/437 ,  C07D471/04 ,  C07D519/00 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/635 ,  A61K31/444

Abstract: The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

公开(公告)号：US10335414B2

公开(公告)日：2019-07-02

申请号：US14647387

申请日：2013-12-03

Applicant: Indiana University Research and Technology Corporation

Inventor： Vincent Gattone ,  Bonnie Blazer-Yost

IPC: A61K31/00 ,  A61K31/18 ,  A61M27/00 ,  A61K31/165 ,  A61K31/4439 ,  A61K31/28 ,  A61K31/55 ,  A61K31/202 ,  A61K31/225 ,  A61K31/405 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4995

Abstract: The present invention provides uses of TRPV4 antagonists in the treatment or prevention of hydrocephalus symptoms, also known as hydrocephaly, including hydrocephalus as a result of any structural defect, any metabolic defect, any injury (direct force to the head, indirect force to the head, shock waves, pressure changes, etc.), any insult (microbial, chemical, toxins, allergic reactions or other inflammatory process, or other pathology, eg. cancer, benign tumor, etc.). Related materials and methods are also provided herein.

公开(公告)号：US20190175602A1

公开(公告)日：2019-06-13

申请号：US16326039

申请日：2017-08-14

Applicant: Wensheng Yu ,  LING Tong ,  Joseph A. Koziowski ,  Craig: A Coburn ,  De-yi J. Yang ,  Deyou Sha ,  Jae-Hun. Kim ,  Michael Dwyer ,  Kartik M. Keertikar ,  Bin Hu ,  Bin Zhong ,  Jinglai Hao ,  Dahai Wang

Inventor： Wensheng Yu ,  LING Tong ,  Joseph A. Koziowski ,  Craig: A Coburn ,  De-yi J. Yang ,  Deyou Sha ,  Jae-Hun. Kim ,  Michael Dwyer ,  Kartik M. Keertikar ,  Bin Hu ,  Bin Zhong ,  Jinglai Hao ,  Dahai Wang

IPC: A61K31/5365 ,  C07D498/04 ,  A61P31/14 ,  A61K31/4995 ,  C07D519/00

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetra-cyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.